title: IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease.
authors.affiliation: Department of Pharmacological and Biomolecular Sciences University of Milan and IRCCS Multimedica, Via Balzaretti 9, 20133 Milano, Italy. Electronic address: alberico.catapano@unimi.it.
authors.forename: Alberico L
authors.initials: AL
authors.lastname: Catapano
authors.affiliation: Division of Cardiovascular Medicine Wayne State University School of Medicine UHC, 2E2 Detroit, MI 48202, USA.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Ference
mesh_terms: D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology / Q000235:genetics*; D008078:Cholesterol, LDL / Q000097:blood*; D017277:Drug Approval; D000069438:Ezetimibe / Q000008:administration & dosage; D020022:Genetic Predisposition to Disease; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008565:Membrane Proteins / Q000235:genetics; D026901:Membrane Transport Proteins; D057182:Mendelian Randomization Analysis; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; C410800:NPC1L1 protein, human; D000069438:Ezetimibe